OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Gomella on Enzalutamide in Prostate Cancer

February 27th 2018

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses enzalutamide (Xtandi) for patients with nonmetastatic castration-resistant prostate cancer.

Dr. Mutch on Biomarkers in Endometrial Cancer

February 27th 2018

David Mutch, MD, Ira C. and Judith Gall professor, vice chair of obstetrics and gynecology, chief, Division of Gynecologic Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses molecular biomarkers in endometrial cancer.

Dr. Weksler on Neoadjuvant and Adjuvant Therapy in NSCLC

February 27th 2018

Benny Weksler, MD, FACS, chief, Division of Thoracic Surgery, professor, Surgery, University of Tennessee Health Science Center, Eastridge-Cole Endowed Professor of Thoracic Surgery, West Cancer Center, discusses the role of minimally-invasive surgery in the stages of non–small cell lung cancers (NSCLC).

Dr. Gieschen on the Side Effects of Radiation Therapy in NSCLC

February 27th 2018

Holger L. Gieschen, MD, assistant professor, Department of Radiology, the University of Tennessee Health Science Center, radiation oncologist, West Cancer Center, discusses the safety profile of radiation therapy in patients with non–small cell lung cancers (NSCLC).

Dr. Finn on the FDA Approval of Frontline Abemaciclib in HR+/HER2- Breast Cancer

February 27th 2018

Richard S. Finn, an associate professor of medicine at the Geffen School of Medicine at the University of California, Los Angeles, discusses the FDA approval of abemaciclib (Verzenio) for use in combination with an aromatase inhibitor for the frontline treatment of women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer.

Dr. Borghaei Discusses the PACIFIC Trial in Lung Cancer

February 27th 2018

Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the PACIFIC trial in patients with non–small cell lung cancer (NSCLC).

Dr. Plimack on Immunotherapy Combinations in Bladder Cancer

February 27th 2018

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses immunotherapy combinations for patients with bladder cancer.

Dr. Ramalingam on Pembrolizumab and Chemotherapy in NSCLC

February 27th 2018

Suresh A. Ramalingam, MD, deputy director of Winship Cancer Institute of Emory University, discusses data with pembrolizumab (Keytruda) and chemotherapy in patients with non–small cell lung cancer (NSCLC).

Dr. Hill Discusses Combinations in MCL

February 26th 2018

Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses combinations for the treatment of patients with mantle cell lymphoma.

Dr. Klopp Discusses Chemoradiation in Endometrial Cancer

February 26th 2018

Ann H. Klopp, MD, PhD, an associate professor of radiation oncology at The University of Texas MD Anderson Cancer Center, discusses chemoradiation in endometrial cancer.

Dr. Mell Discusses Flaws in Risk Stratification for Head and Neck Cancer

February 26th 2018

Loren K. Mell, MD, assistant professor, Department of Radiation Medicine and Applied Sciences, University of California, San Diego School of Medicine, discusses flaws in the current model of risk stratification for patients with head and neck cancer.

Dr. Andtbacka Discusses the Role of T-VEC in Melanoma

February 24th 2018

Robert Andtbacka, MD, associate professor in the Division of Surgical Oncology, Department of Surgery at the University of Utah School of Medicine, discusses the role of talimogene laherparapvec (T-VEC; Imlygic) in the treatment of patients with melanoma.

Dr. Portnoy on the Importance of Driver Mutations in the Treatment of NSCLC

February 24th 2018

David C. Portnoy, MD, medical oncologist and hematologist, West Cancer Center, discusses the importance of driver mutations in the treatment of non–small cell lung cancer (NSCLC).

Dr. Berdeja Discusses the Future of Treatment for Myeloma

February 24th 2018

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses the future of treatment for patients with myeloma.

Dr. Grupka on Mutations in Patients With Myelodysplastic Syndrome

February 24th 2018

Nichon L. Grupka, MD, pathologist, Novant Health Thomasville Medical Center, discusses the manifestations of mutations in myelodysplastic syndrome (MDS).

Dr. Bachier on the Evolution of Stem Cell Transplants in Hematologic Malignancies

February 24th 2018

Carlos R. Bachier, MD, director, blood and marrow transplant research, Sarah Cannon Research Institute, discusses the advancement of supportive care in hematologic malignancies.

Dr. Moore Discusses Combinations in Ovarian Cancer

February 23rd 2018

Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses combinations in the treatment of patients with ovarian cancer.

Dr. West on the Future of Treatment for Patients With Gynecologic Malignancies

February 23rd 2018

Lindsay West, MD, gynecologic oncologist, University of North Carolina (UNC) Department of Obstetrics and Gynecology, UNC School of Medicine, discusses the future of treatment for patients with gynecologic malignancies.

Dr. Slovin Discusses GnRH Antagonists Versus Agonists

February 23rd 2018

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the difference between GnRH antagonists and GnRH agonists.

Dr. McKay on Unmet Needs for RCC

February 23rd 2018

Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses unmet needs for patients with renal cell carcinoma (RCC).